Estrella Immunopharma EBIT

As of the most recent data (June 2026), ESLA shows a EBIT of $-9.7M. That compares with $-12M in the prior-year period — up 19.8% year over year. That is below the sector sector average of $-6.4M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ESLA's EBIT is now $-9.7M (was $-12M) — a 19.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Estrella Immunopharma is outperforming or lagging.

The its sector sector average EBIT is about $-6.4M. Estrella Immunopharma is at $-9.7M, which is lower that average. That is roughly 51.2% below the sector mean. Use the comparison chart on this page to see how ESLA stacks up against individual peers as well.

Tracking ESLA's ebit over time shows whether Estrella Immunopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-9.7M That compares with $-12M in the prior-year period — up 19.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Estrella Immunopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-9.7M) with ownership activity and broader fundamentals.